These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 4146086)

  • 21. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
    Dhaneshwar SS; Kandpal M; Vadnerkar G; Rathi B; Kadam SS
    Eur J Med Chem; 2007 Jun; 42(6):885-90. PubMed ID: 17258353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
    Munk EM; Pedersen L; Floyd A; Nørgård B; Rasmussen HH; Sørensen HT
    Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
    Dhaneshwar SS; Gairola N; Kandpal M; Vadnerkar G; Bhatt L; Rathi B; Kadam SS
    Eur J Med Chem; 2009 Oct; 44(10):3922-9. PubMed ID: 19442419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis.
    Klotz U
    Dig Liver Dis; 2005 Jun; 37(6):381-8. PubMed ID: 15893274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to treatment of microscopic colitis.
    Fasoli R; Jewell DP
    Ital J Gastroenterol; 1994 Jun; 26(5):229-32. PubMed ID: 7919463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products.
    Dzierzewicz Z; Cwalina B; Weglarz L; Wiśniowska B; Szczerba J
    Med Sci Monit; 2004 Jun; 10(6):BR185-90. PubMed ID: 15173665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetics of Azulfidine/Salazopyrin in healthy humans and in patients with chronic inflammatory bowel diseases].
    Van Hees PA
    Z Gastroenterol Verh; 1981 Jun; 19():7-14. PubMed ID: 6168136
    [No Abstract]   [Full Text] [Related]  

  • 28. [Salozosulphapyridine and its metabolites in ulcerative colitis and Crohn disease].
    Rubinstein BE
    Ugeskr Laeger; 1982 Feb; 144(5):304-6. PubMed ID: 6122297
    [No Abstract]   [Full Text] [Related]  

  • 29. Will there be a next generation of sulfasalazine?
    Goldman P
    Gastroenterology; 1982 Nov; 83(5):1138-41. PubMed ID: 6126420
    [No Abstract]   [Full Text] [Related]  

  • 30. [Comparative efficacy of mezakol and sulfasalazine in treating chronic relapsing ulcerative colitis].
    Rogozina VA; Rumiantsev VG
    Eksp Klin Gastroenterol; 2003; (1):58-9, 183. PubMed ID: 12664788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of iron and calcium on salicylazosulphapyridine metabolism.
    Das KM; Eastwood MA
    Scott Med J; 1973 Mar; 18(2):45-50. PubMed ID: 4144706
    [No Abstract]   [Full Text] [Related]  

  • 32. Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzenesulfonic acid-induced colitis in rats.
    Dhaneshwar SS; Gairola N; Kandpal M; Vadnerkar G; Bhatt L
    Bioorg Med Chem; 2007 Jul; 15(14):4903-9. PubMed ID: 17499512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The treatment of ulcerative colitis].
    Turunen U; Järvinen HJ
    Duodecim; 1993; 109(2):145-51. PubMed ID: 7912179
    [No Abstract]   [Full Text] [Related]  

  • 36. [Discussion apropos of a case of ulcerative colitis].
    Loizeau E
    Rev Med Suisse Romande; 1995 Mar; 115(3):263-6. PubMed ID: 7777769
    [No Abstract]   [Full Text] [Related]  

  • 37. Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.
    Dhaneshwar SS; Chail M; Patil M; Naqvi S; Vadnerkar G
    Eur J Med Chem; 2009 Jan; 44(1):131-42. PubMed ID: 18472188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
    Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
    J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The treatment of inflammatory diseases of the colon with salazopyrine].
    Chevrel B
    Med Chir Dig; 1982; 11(3):227-30. PubMed ID: 6124663
    [No Abstract]   [Full Text] [Related]  

  • 40. [Microscopic colitis. A 20 cases series].
    Fekih M; Ben Hriz F; Sassi A; Matri S; Filali A; Boubaker J
    Tunis Med; 2006 Jul; 84(7):403-6. PubMed ID: 17039729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.